Adjuvant without active component

( DrugBank: - / KEGG DRUG: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

告示番号	疾患名（ページ内リンク）	臨床試験数
17	多系統萎縮症	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02758730 (ClinicalTrials.gov)	November 2015	26/4/2016	Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of ...	A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study A ...	Parkinson's Disease	Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component	Affiris AG	University Hospital Tuebingen	Withdrawn	40 Years	80 Years	Both	0	Phase 1	Germany
2	NCT02267434 (ClinicalTrials.gov)	December 2014	4/9/2014	Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Diseas ...	A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study ...	Parkinson Disease;Neurodegenerative Diseases	Biological: Low dose AFFITOPE® PD03A + Adjuvant;Biological: High dose AFFITOPE® PD03A + Adjuvant;Bio ...	Affiris AG	PROSENEX AmbulatoriumbetriebsGMBH;Medical University Innsbruck;Forschungszentrum Juelich	Completed	45 Years	70 Years	Both	36	Phase 1	Austria

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02270489 (ClinicalTrials.gov)	December 11, 2014	4/9/2014	Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early ...	A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety ...	Multiple System Atrophy;Neurodegenerative Diseases	Biological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant w ...	Affiris AG	University Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Fors ...	Completed	30 Years	75 Years	All	30	Phase 1	France